Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.

Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
复制标题

DOI:
10.3390/ijms22136916
复制
发表时间:
2021-06-28
影响因子:
5.6
通讯作者:
Ajjan RA
Ajjan RA
中科院分区:
生物学2区
文献类型:
--
作者:
Gaule TG;Ajjan RA

文献摘要

参考文献

被引文献

相似文献

纤维蛋白原是止血的关键分子之一。凝血酶介导的纤维蛋白肽从纤维蛋白原的释放将这种可溶性蛋白质转化为纤维蛋白纤维的网络,其形成血凝块的构建块。凝血酶激活因子XIII进一步交联纤维蛋白纤维,并将抗纤维蛋白溶解蛋白纳入网络中,从而稳定凝块。纤维蛋白原向纤维蛋白的转化也暴露了纤维蛋白溶解蛋白的结合位点,以限制凝块形成并避免纤维蛋白纤维的不必要的延伸。改变的凝块结构和/或抗纤维蛋白溶解蛋白掺入纤维蛋白网络扰乱了凝块形成和溶解之间的微妙平衡,导致不稳定的凝块(易发生出血事件)或对溶解有抵抗力的持续性凝块(增加血栓形成的风险)。在这篇综述中,我们讨论了纤维蛋白(原)的变化,可以调节凝块的稳定性,反过来诱发异常止血的因素。我们还探讨了可能允许使用纤维蛋白原作为治疗血管血栓形成或出血性疾病的潜在治疗靶点的机制途径。更好地了解纤维蛋白原的功能将有助于设计未来有效和安全的治疗方法来调节血栓形成和出血风险,同时保持凝块形成和溶解之间的良好平衡。
Fibrinogen is one of the key molecular players in haemostasis. Thrombin-mediated release of fibrinopeptides from fibrinogen converts this soluble protein into a network of fibrin fibres that form a building block for blood clots. Thrombin-activated factor XIII further crosslinks the fibrin fibres and incorporates antifibrinolytic proteins into the network, thus stabilising the clot. The conversion of fibrinogen to fibrin also exposes binding sites for fibrinolytic proteins to limit clot formation and avoid unwanted extension of the fibrin fibres. Altered clot structure and/or incorporation of antifibrinolytic proteins into fibrin networks disturbs the delicate equilibrium between clot formation and lysis, resulting in either unstable clots (predisposing to bleeding events) or persistent clots that are resistant to lysis (increasing risk of thrombosis). In this review, we discuss the factors responsible for alterations in fibrin(ogen) that can modulate clot stability, in turn predisposing to abnormal haemostasis. We also explore the mechanistic pathways that may allow the use of fibrinogen as a potential therapeutic target to treat vascular thrombosis or bleeding disorders. Better understanding of fibrinogen function will help to devise future effective and safe therapies to modulate thrombosis and bleeding risk, while maintaining the fine balance between clot formation and lysis.
DOI: 10.1161/atvbaha.109.183707
发表时间: 2009-05-01
影响因子: 8.7
作者:
Ajjan, R. A.;Standeven, K. F.;Grant, P. J.
通讯作者: Grant, P. J.
DOI: 10.1586/14779072.3.6.1047
发表时间: 2005-11-01
影响因子: 2
作者:
Ajjan, Ramzi A;Grant, Peter J
通讯作者: Grant, Peter J
DOI: 10.1111/j.1432-1033.1988.tb13900.x
发表时间: 1988-03-01
期刊: EUROPEAN JOURNAL OF BIOCHEMISTRY
影响因子: --
作者:
BOSMA, PJ;RIJKEN, DC;NIEUWENHUIZEN, W
通讯作者: NIEUWENHUIZEN, W
DOI: 10.1182/blood-2015-06-652263
发表时间: 2015-10-15
期刊: BLOOD
影响因子: 20.3
作者:
Byrnes, James R.;Duval, Cedric;Wolberg, Alisa S.
通讯作者: Wolberg, Alisa S.
DOI: 10.1161/01.cir.93.3.440
发表时间: 1996-02-01
期刊: CIRCULATION
影响因子: 37.8
作者:
Behague, I;Poirier, O;Cambien, F
通讯作者: Cambien, F